NO20072839L - 4-hydroksybenzomorfaner - Google Patents

4-hydroksybenzomorfaner

Info

Publication number
NO20072839L
NO20072839L NO20072839A NO20072839A NO20072839L NO 20072839 L NO20072839 L NO 20072839L NO 20072839 A NO20072839 A NO 20072839A NO 20072839 A NO20072839 A NO 20072839A NO 20072839 L NO20072839 L NO 20072839L
Authority
NO
Norway
Prior art keywords
hydroksybenzomorfaner
hydroxybenzomorphans
thiocarboxamide
antitussives
anticonvulsants
Prior art date
Application number
NO20072839A
Other languages
English (en)
Other versions
NO340204B1 (no
Inventor
Mark P Wentland
Original Assignee
Rensselaer Polytech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytech Inst filed Critical Rensselaer Polytech Inst
Publication of NO20072839L publication Critical patent/NO20072839L/no
Publication of NO340204B1 publication Critical patent/NO340204B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

4-Hydroksybenzomorfaner som inneholder karboksamid eller tiokarboksamid i 3-posisjon er nyttige som analgetiske midler, anti-diaré midler, antikonvulsanter, antitussiver og anti-avhengighet medisinering.
NO20072839A 2004-11-05 2007-06-04 4-hydroksybenzomorfaner NO340204B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534804P 2004-11-05 2004-11-05
PCT/US2005/039911 WO2006052710A1 (en) 2004-11-05 2005-11-03 4-hydroxybenzomorphans

Publications (2)

Publication Number Publication Date
NO20072839L true NO20072839L (no) 2007-08-03
NO340204B1 NO340204B1 (no) 2017-03-20

Family

ID=36128632

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072839A NO340204B1 (no) 2004-11-05 2007-06-04 4-hydroksybenzomorfaner

Country Status (20)

Country Link
US (7) US7262298B2 (no)
EP (2) EP1817291A1 (no)
JP (3) JP5198067B2 (no)
KR (1) KR101115841B1 (no)
CN (1) CN101090891B (no)
AT (1) ATE557006T1 (no)
AU (1) AU2005304950B2 (no)
BR (1) BRPI0517091B8 (no)
CA (1) CA2587074C (no)
CY (1) CY1112946T1 (no)
DK (1) DK2251330T3 (no)
ES (1) ES2387737T3 (no)
IL (1) IL182983A (no)
MX (1) MX2007005389A (no)
NO (1) NO340204B1 (no)
PL (1) PL2251330T3 (no)
PT (1) PT2251330E (no)
RU (2) RU2415131C2 (no)
SI (1) SI2251330T1 (no)
WO (1) WO2006052710A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239170T3 (es) 2000-10-31 2005-09-16 Rensselaer Polytechnic Institute 2,6-metano-3-benzazocinas sustituidas en posicion 8 y morfinanos sustituidos en posicion 3 como agentes ligantes a receptores opioides.
RU2415131C2 (ru) * 2004-11-05 2011-03-27 Ренссилэйер Политекник Инститьют 4-гидроксибензоморфаны
EP1924559B1 (en) 2005-07-21 2014-04-16 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
JP2009534472A (ja) 2007-05-04 2009-09-24 マリンクロッド・インコーポレイテッド ６−アルファ−ヒドロキシ−ｎ−アルキル化オピエート類の改良型製造方法
JP2010533719A (ja) 2007-07-17 2010-10-28 マリンクロッド・インコーポレイテッド 還元的アミノ化によるｎ−アルキル化オピエートの調製
US8263807B2 (en) 2007-08-09 2012-09-11 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
CA2738628C (en) 2008-09-30 2017-07-04 Mallinckrodt Inc. Processes for the selective amination of ketomorphinans
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
AU2009342654B2 (en) * 2009-03-19 2013-09-05 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
US20100261906A1 (en) * 2009-04-09 2010-10-14 Mallinckrodt Inc. Preparation of 6-Keto, 3-Alkoxy Morphinans
CN102459274B (zh) 2009-06-11 2015-07-15 马林克罗特有限公司 6-酮基去甲吗啡喃通过催化氢转移的还原胺化
PL2440562T3 (pl) 2009-06-11 2017-07-31 Mallinckrodt Llc Otrzymywanie 6-alfa-amino-N-podstawionych morfinanów w wyniku katalitycznego przeniesienia wodoru
DK2506712T3 (da) 2009-12-04 2019-06-03 Alkermes Pharma Ireland Ltd Morfinanderivater til behandling af lægemiddeloverdosering
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
PL2563793T3 (pl) * 2010-04-29 2015-03-31 SpecGx LLC Wytwarzanie nasyconych związków ketonowych morfinanu o niskiej zawartości metalu
JP5728084B2 (ja) 2010-07-08 2015-06-03 アルカーメス ファーマ アイルランド リミテッド 置換モルフィナンの合成のための方法
LT3446565T (lt) 2010-08-23 2024-01-10 Alkermes Pharma Ireland Limited Antipsichozinių vaistų sukelto svorio augimo gydymo būdai
US9029543B2 (en) 2011-04-05 2015-05-12 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
PL2718294T3 (pl) 2011-06-09 2019-04-30 SpecGx LLC Redukcyjne aminowanie 6-keto morfinanów przez katalityczne przeniesienie wodoru
ES2638329T3 (es) 2011-06-29 2017-10-19 Alkermes, Inc. Compuestos opioides de acción periférica
JP2014526467A (ja) 2011-09-08 2014-10-06 マリンクロッド エルエルシー 中間体の単離なしでのアルカロイドの調製
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
SI3153171T1 (sl) 2011-12-15 2019-01-31 Alkermes Pharma Ireland Limited Samidorfan (ALKS 33) v kombinaciji z buprenorfinom za zdravljenje depresivnih motenj
CA2911231C (en) 2013-05-24 2021-12-07 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
KR20190120212A (ko) * 2017-03-02 2019-10-23 가부시키가이샤산와카가쿠켄큐쇼 알코올 사용 장해의 치료약
CN107089948B (zh) * 2017-04-28 2020-07-17 云南大学 吗吩衍生物及其制备方法和应用
CN111978252A (zh) * 2019-05-21 2020-11-24 复旦大学 手性苯并吗吩烷类衍生物及其制备方法和在药学上的应用
TW202140009A (zh) * 2020-02-13 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 ３－甲醯胺基－４－羥基納曲酮氘代衍生物、其製備方法及其在醫藥上的應用
CN111205151B (zh) * 2020-02-29 2021-03-05 深圳市祥根生物科技有限公司 一种布洛芬杂质i的环保制备方法
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
KR102663533B1 (ko) * 2021-11-09 2024-05-08 백미선 레이저 치료기기용 온냉각장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) * 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4205171A (en) * 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) * 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4649200A (en) * 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
BR9707136A (pt) 1996-01-10 1999-08-31 Smithkline Beecham Spa Derivados morfinóides condesados em heterociclo (ii)
ES2239170T3 (es) * 2000-10-31 2005-09-16 Rensselaer Polytechnic Institute 2,6-metano-3-benzazocinas sustituidas en posicion 8 y morfinanos sustituidos en posicion 3 como agentes ligantes a receptores opioides.
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
RU2415131C2 (ru) * 2004-11-05 2011-03-27 Ренссилэйер Политекник Инститьют 4-гидроксибензоморфаны

Also Published As

Publication number Publication date
US20160075658A1 (en) 2016-03-17
US8802655B2 (en) 2014-08-12
BRPI0517091B1 (pt) 2019-10-08
CY1112946T1 (el) 2016-04-13
AU2005304950A1 (en) 2006-05-18
CA2587074C (en) 2012-09-04
RU2010147915A (ru) 2012-05-27
RU2007120759A (ru) 2008-12-10
US20140148475A1 (en) 2014-05-29
CN101090891B (zh) 2012-08-01
EP2251330B1 (en) 2012-05-09
DK2251330T3 (da) 2012-08-06
IL182983A0 (en) 2007-08-19
JP2016020364A (ja) 2016-02-04
EP1817291A1 (en) 2007-08-15
ATE557006T1 (de) 2012-05-15
US8680112B2 (en) 2014-03-25
CA2587074A1 (en) 2006-05-18
JP5198067B2 (ja) 2013-05-15
EP2251330A1 (en) 2010-11-17
US20130231361A1 (en) 2013-09-05
PT2251330E (pt) 2012-07-20
ES2387737T3 (es) 2012-10-01
KR20070085723A (ko) 2007-08-27
CN101090891A (zh) 2007-12-19
US20240092740A1 (en) 2024-03-21
JP2013067636A (ja) 2013-04-18
PL2251330T3 (pl) 2012-12-31
US20070238748A1 (en) 2007-10-11
US20060111384A1 (en) 2006-05-25
RU2415131C2 (ru) 2011-03-27
US20150011768A1 (en) 2015-01-08
IL182983A (en) 2012-06-28
RU2480455C2 (ru) 2013-04-27
AU2005304950B2 (en) 2010-12-09
BRPI0517091B8 (pt) 2021-05-25
BRPI0517091A (pt) 2008-09-30
SI2251330T1 (sl) 2012-09-28
WO2006052710A1 (en) 2006-05-18
US7262298B2 (en) 2007-08-28
NO340204B1 (no) 2017-03-20
JP6058981B2 (ja) 2017-01-11
JP2008519035A (ja) 2008-06-05
MX2007005389A (es) 2007-12-07
KR101115841B1 (ko) 2012-03-09

Similar Documents

Publication Publication Date Title
NO20072839L (no) 4-hydroksybenzomorfaner
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
NO20043803L (no) Substituerte amider som er aktive i cannabinoid 1-reseptoren
NO20052739D0 (no) CCR5-antagonister som medikamenter
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування
NO20014963D0 (no) Cycloalkyl-substituerte benzimidazoler, samt fremstilling og anvendelse derav
WO2004028475A3 (en) Glycosylceramide analogues
DK1667668T3 (da) Alfabeta3 og altabeta6-integrinantagonister som antifibrotiske midler
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
MX2007007355A (es) 5-(2,2-dimetil-ciclopropil)-3-metil-pen-2-en nitrilo como fragancia y sabor.
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
DE60319388D1 (de) C6- UND C9-SUBSTITUIERTE CHROMENOÄ4,3-cÜISOXAZOLIN
FR2835436B1 (fr) Instrumentation pour analgesie, notamment peridurale
ITBS20030025A1 (it) Dispositivo di comando per sedie da ufficio e simili.
ITMI20022781A1 (it) Composizione per prodotti dermatologici ad azione topica e prodotti dermatologici realizzati con questa composizione.
ITGE20030111A1 (it) Anta, in particolare per armadi e simili.
IT248493Y1 (it) Anta sagomata per mobili e simili.
FR2836043B1 (fr) Vesicules lipidiques, preparation et utilisations
ITPD20030307A1 (it) Slamatore con bloccaggio dell'amo
ITMI20030317A1 (it) Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
ITMI20022352A1 (it) Preparazioni antitumorali contenenti resveratrolo e propoli.
ES1053325Y (es) Pastilla-mascara para tratamientos faciales.
IT1320633B1 (it) Procedimento implementato da calcolatore per la pubblicazione, laconsultazione e la vendita di opere letterarie e/o artistiche.
ITPC20020028A1 (it) Struttura per porcilaie o simili.